Staedt 1997.

Methods	Randomised active controlled crossover trial of levodopa versus pergolide Dropouts/withdrawals: Total N of 11, no premature discontinuations
Participants	Included/analysed: 11 Demographics: 6 male, age 57.6 years Diagnosis: patients with a history of restlessness and paraesthesias at night and/or day Setting: 1 centre in Germany Baseline: PLMS‐disturbed time of sleep 164 ± 80.4 min
Interventions	Intervention 1: flexible uptitration of single dose levodopa/benserazide from 200 mg/50 mg to 400 mg/100 mg in 16 days Intervention 2: flexible uptitration of single dose pergolide from 0.125 mg to 0.25 mg in 16 days Washout of 24 hours between treatment periods
Outcomes	Objective quality of sleep: Change in sleep parameters (TST) Safety: Number of dropouts due to adverse events, number of patients experiencing adverse events
funding source	No funding stated.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Insufficient information.
Allocation concealment?	Unclear risk	Insufficient information.
Blinding? All outcomes	Unclear risk	Insufficient information, not mentioned if research staff were blinded.
Incomplete outcome data addressed? All outcomes	Low risk	No incomplete outcome data.
Free of selective reporting?	Low risk	All results reported as prespecified, additional sleep data reported.
Free of other bias?	Low risk	Low indication of bias.